Summit Therapeutics Inc. Enters Material Definitive Agreement
Ticker: SMMT · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, sec-filing
TL;DR
Summit Therapeutics just signed a big deal, filing an 8-K on 6/20.
AI Summary
On June 16, 2025, Summit Therapeutics Inc. entered into a material definitive agreement. The company, headquartered in Miami, FL, filed an 8-K report with the SEC on June 20, 2025, detailing this significant event.
Why It Matters
This filing indicates a significant business development for Summit Therapeutics Inc., potentially impacting its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Entering a material definitive agreement can introduce new risks or opportunities, the nature of which is not detailed in this initial filing.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- June 16, 2025 (date) — Date of Earliest Event Reported
- June 20, 2025 (date) — Filing Date
- Miami, FL (location) — Principal Executive Offices
FAQ
What type of material definitive agreement did Summit Therapeutics Inc. enter into?
The filing states that the company entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 16, 2025.
On what date was this 8-K filing submitted to the SEC?
The filing was submitted on June 20, 2025.
What is the principal executive office address for Summit Therapeutics Inc.?
The principal executive offices are located at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
What is the IRS Employer Identification Number for Summit Therapeutics Inc.?
The IRS Employer Identification Number is 37-1979717.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Summit Therapeutics Inc. (SMMT).